21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 53
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Dror Ben-Asher | Co-Founder, Chairman & CEO | 594.61k | N/D | 1966 |
Mr. Razi Ingber | Chief Financial Officer | 339.82k | N/D | 1984 |
Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 365.56k | N/D | 1975 |
Mr. Adi Frish | Chief Corporate & Business Development Officer | 339.3k | N/D | 1970 |
Mr. Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director | 469.8k | N/D | 1960 |
Ms. Alexandra Okmian | Senior Business Development & Investor Relations Manager | N/D | N/D | N/D |
Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development | 299.29k | N/D | 1955 |
Mr. Guy Goldberg J.D. | Chief Business Officer | 338.13k | N/D | 1976 |
Dr. June S. Almenoff FACP, M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1957 |
Ms. Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
La calificación ISS Governance QuickScore de RedHill Biopharma Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.